Yes, say the folks at Nomura, who recommend buying Celgene (CELG), Receptos (RCPT), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), and Alexion Pharmaceuticals (ALXN), in that order. Analyst M. Ian Somaiya and team explain why: October has historically been a weak month for biotech, with the Nasdaq Biotechnology Index underperforming the … Read entire story.
Source: Stocks to Watch